BeiGene, Ltd. (NASDAQ:BGNE) Director Bros. Advisors Lp Baker Sells 1,037,017 Shares of Stock

BeiGene, Ltd. (NASDAQ:BGNE) Director Bros. Advisors Lp Baker sold 1,037,017 shares of BeiGene stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $187.27, for a total value of $194,202,173.59. Following the completion of the transaction, the director now directly owns 791,493 shares of the company’s stock, valued at $148,222,894.11. This represents a 56.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

BeiGene Stock Down 9.7 %

NASDAQ:BGNE opened at $187.50 on Wednesday. The firm’s 50 day simple moving average is $210.61 and its 200 day simple moving average is $186.53. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. BeiGene, Ltd. has a one year low of $126.97 and a one year high of $248.16. The company has a market cap of $18.27 billion, a PE ratio of -22.75 and a beta of 0.57.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The firm’s revenue for the quarter was up 28.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.01 EPS. On average, research analysts anticipate that BeiGene, Ltd. will post -5.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. StockNews.com cut BeiGene from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JPMorgan Chase & Co. upped their target price on shares of BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday, October 22nd. TD Cowen upped their target price on shares of BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Morgan Stanley reaffirmed an “overweight” rating and issued a $300.00 target price on shares of BeiGene in a research note on Tuesday, December 3rd. Finally, JMP Securities assumed coverage on shares of BeiGene in a research report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.69.

Institutional Trading of BeiGene

Several hedge funds have recently modified their holdings of BGNE. Blue Trust Inc. increased its stake in BeiGene by 156.3% during the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company’s stock valued at $28,000 after purchasing an additional 75 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in BeiGene during the 3rd quarter valued at $36,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in BeiGene during the 3rd quarter valued at $67,000. SG Americas Securities LLC bought a new stake in BeiGene during the 3rd quarter valued at $105,000. Finally, PFG Investments LLC bought a new stake in BeiGene during the 3rd quarter valued at $210,000. Institutional investors own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.